Myeloma XI: Paired Presentation, Relapse and Control Samples From Newly Diagnosed, Uniformly Treated Myeloma Patients
UID: 10516
- Description
Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI) was a randomized controlled trial which recruited 4420 adult patients in the United Kingdom who were newly diagnosed with symptomatic or non-secretory multiple myeloma to study the use of thalidomide, bortezomib, lenalidomide, carfilzomib and vorinostat in their initial treatment plans.
This dataset contains 131 presentation, relapse, and control samples from 56 patients in the Myeloma XI trial who were considered high risk and relapsed within 30 months of randomization to the observation or lenalidomide maintenance groups. 37 additional samples are shared under EGA accession identifier EGAD00001001358 (see Related Datasets). The samples underwent whole exome sequencing with targeted capture of the IGH/K/L and MYC loci.- Timeframe
- 2010 - 2019
- Geographic Coverage
-
United Kingdom
- Local Expert
Homo sapiens
Subject Domain
Population Age
Keywords
Adult (19 years - 64 years)
Senior (65 years - 79 years)
Aged (80 years and over)
Access
- Restrictions
-
Application RequiredAuthor Approval Required
- Instructions
- Whole exome sequencing data has been shared with controlled access through the European Genome-phenome Archive (EGA) repository. To request access, interested investigators must submit their study proposals and requests for collaboration to Dr. Gareth Morgan through the Local Expert contact form.
Observational
- PubMed Search
- View articles which use this dataset
- Other Resources
-
ClinicalTrials.gov
NCT01554852
- Related Datasets
Do you have or know of a dataset that should be added to the catalog? Let us know!